Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPVUGE)

Drug Name

CDX-1127 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
leukaemia	2A60-2B33	Phase 1	[1]
Lymphoma	2A80-2A86	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cell activation antigen CD27 (CD27)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Varlilumab	DMQSC5O	Colorectal cancer	2B91.Z	Phase 2	[3]
CDX-527	DMVDIWO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell activation antigen CD27 (CD27)	TTDO1MV	CD27_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02284971) Pilot Study of SBRT and CDX-1127 in Prostate Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Celldex Therapeutics.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137.